Inhibition of IGF-IR increases chemosensitivity in human colorectal cancer cells through MRP-2 promoter suppression

Journal of Cellular Biochemistry

Volumn 113, Issue 6, 2012, Pages 2086-2097

  Shen, Ke ^a   Cui, Daling ^a   Sun, Liyun ^a   Lu, Yanhua ^a   Han, Mingquan ^a,b   Liu, Jianwen ^a  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

COLORECTAL CANCER; INSULIN LIKE GROWTH FACTOR TYPE I; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE; RNA INTERFERENCE

Indexed keywords

FLUOROURACIL; MITOMYCIN C; MULTIDRUG RESISTANCE PROTEIN 2; OXALIPLATIN; SMALL INTERFERING RNA; SOMATOMEDIN C RECEPTOR; VINCRISTINE;

ARTICLE; CHEMOSENSITIVITY; COLORECTAL CANCER; CONTROLLED STUDY; DRUG RESPONSE; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RECEPTOR INTRINSIC ACTIVITY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NF-E2-RELATED FACTOR 2; PHOSPHATIDYLINOSITOL 3-KINASES; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, IGF TYPE 1; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84859583479     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24080     Document Type: Article

References (37)

1. Amin HM, Shi P, Lai R, Lin Q, Iqbal AS, Young LC, Kwak LW, Ford RJ,. 2010. IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK(+) anaplastic large-cell lymphoma cells. Blood 114: 360-370.
2. Boccaccio C, Comoglio PM,. 2006. Invasive growth: A MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 6: 637-645.
3. Castanotto D, Rossi JJ,. 2009. The promises and pitfalls of RNA-interference-based therapeutics. Nature 457: 426-433.
4. Chakraborty AK, Welsh A, DiGiovanna MP,. 2010. Co-targeting the insulin-like growth factor I receptor enhances growth-inhibitory and pro-apoptotic effects of anti-estrogens in human breast cancer cell lines. Breast Cancer Res Treat 120: 327-335.
5. Cui Y, König J, Buchholz U, Spring H, Leier I, Keppler D,. 1999. Drug Resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 55: 929-937.
6. Dallas NA, Xia L, Fan F, Yang AD, Gray MJ, Samuel S, Gaur P, Ellis LM,. 2008. Chemo-resistant colorectal cancer cells are enriched for tumor stem cells and sensitive to IGF-1R inhibition. J Am Coll Surg 207: S99.
7. Dallas NA, Xia L, Fan F, Gray MJ, Gaur P, van Buren G, Samuel S, Kim MP, Lim SJ, Ellis LM,. 2009. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res 69: 1951-1957.
8. Düvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL, Triantafellow E, Ma Q, Gorski R, Cleaver S, Vander Heiden MG, MacKeigan JP, Finan PM, Clish CB, Murphy LO, Manning BD,. 2010. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell 39: 171-183.
9. Ericson K, Gan C, Cheong I, Rago C, Samuels Y, Velculescu VE, Kinzler KW, Huso DL, Vogelstein B, Papadopoulos N,. 2009. Genetic inactivation of AKT1, AKT2, and PDPK1 in human colorectal cancer cells clarifies their roles in tumor growth regulation. Proc Natl Acad Sci USA 107: 2598-2603.
10. Gallagher EJ, LeRoith D,. 2010. The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrin Met 21: 610-618.
11. Garrouste F, Remacle-Bonnet M, Fauriat C, Marvaldi J, Luis J, Pommier G,. 2002. Prevention of cytokine-induced apoptosis by insulin-like growth factor-I is independent of cell adhesion molecules in HT29-D4 colon carcinoma cells-Evidence for a NF-kappa B-dependent survival mechanism. Cell Death Differ 9: 768-779.
12. Haimeur A, Conseil G, Deeley RG, Cole SP,. 2004. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: Biology, substrate specificity and regulation. Curr Drug Metab 5: 21-53.
13. Hart LS, Dolloff NG, Dicker DT, Koumenis C, Christensen JG, Grimberg A, El-Deiry WS,. 2011. Human colon cancer stem cells are enriched by insulin-like growth factor-1 and are sensitive to figitumumab. Cell Cycle 10: 2331-2338.
14. Hopkins A, Crowe P, Yang J-L,. 2010. Effect of type 1 insulin-like growth factor receptor targeted therapy on chemotherapy in human cancer and the mechanisms involved. J Cancer Res Clin Oncol 136: 639-650.
15. Kauffmann H-M, Pfannschmidt S, Zöller H, Benz A, Vorderstemann B, Webster JI, Schrenk D,. 2002. Influence of redox-active compounds and PXR-activators on human MRP1 and MRP2 gene expression. Toxicology 171: 137-146.
16. Kloo B, Nagel D, Pfeifer M, Grau M, Düwel M, Vincendeau M, Dörken B, Lenz P, Lenz G, Krappmann D,. 2011. Critical role of PI3K signaling for NF-κB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci USA 108: 272-277.
17. Li S, Brown MS, Goldstein JL,. 2010. Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proc Natl Acad Sci USA 107: 3441-3446.
18. Liu JW, Yang F, Zhang Y, Li JY,. 2007. Studies on the cell-immunosuppressive mechanism of Oridonin from Isodon serra. Int Immunopharmacol 7: 945-954.
19. Maher JM, Aleksunes LM, Dieter MZ, Tanaka Y, Peters JM, Manautou JE, Klaassen CD,. 2008. Nrf2- and PPARα-mediated regulation of hepatic Mrp transporters after exposure to perfluorooctanoic acid and perfluorodecanoic acid. Toxicol Sci 106: 319-328.
20. Manning BD, Cantley LC,. 2007. AKT/PKB signaling: Navigating downstream. Cell 129: 1261-1274.
21. Min Y, Adachi Y, Yamamoto H, Imsumran A, Arimura Y, Endo T, Hinoda Y, Lee CT, Nadaf S, Carbone DP, Imai K,. 2005. Insulin-like growth factor I receptor blockade enhances chemotherapy and radiation responses and inhibits tumour growth in human gastric cancer xenografts. Gut 54: 591-600.
22. Natrajan R, Reis-Filho JS, Little SE, Messahel B, Brundler M-A, Dome JS, Grundy PE, Vujanic GM, Pritchard-Jones K, Jones C,. 2006. Blastemal expression of Type I insulin-like growth factor receptor in Wilms' Tumors is driven by increased copy number and correlates with relapse. Cancer Res 66: 11148-11155.
23. Ohta T, Iijima K, Miyamoto M, Nakahara I, Tanaka H, Ohtsuji M, Suzuki T, Kobayashi A, Yokota J, Sakiyama T, Shibata T, Yamamoto M, Hirohashi S,. 2008. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res 68: 1303-1309.
24. Roberts EC, Shapiro PS, Nahreini TS, Pages G, Pouyssegur J, Ahn NG,. 2002. Distinct cell cycle timing requirements for extracellular signal-regulated kinase and phosphoinositide 3-kinase signaling pathways in somatic cell mitosis. Mol Cell Biol 22: 7226-7241.
25. Rushworth SA, MacEwan DJ,. 2011. The Role of Nrf2 and cytoprotection in regulating chemotherapy resistance of human leukemia cells. Cancers 3: 1605-1621.
26. Sachdev D, Zhang X, Matise I, Gaillard-Kelly M, Yee D,. 2010. The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival. Oncogene 29: 251-262.
27. Sandusky GE, Mintze KS, Pratt SE, Dantzig AH,. 2002. Expression of multidrug resistance-associated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarrays. Histopathology 41: 65-74.
28. Singh A, Misra V, Thimmulappa RK, Lee H, Ames S, Hoque MO, Herman JG, Baylin SB, Sidransky D, Gabrielson E, Brock MV, Biswal S,. 2006. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med 3: e420.
29. Stöckel B, König J, Nies AT, Cui Y, Brom M, Keppler D,. 2000. Characterization of the 5′-flanking region of the human multidrug resistance protein 2 (MRP2) gene and its regulation in comparison withthe multidrug resistance protein 3 (MRP3) gene. Eur J Biochem 267: 1347-1358.
30. Strömberg T, Ekman S, Girnita L, Dimberg LY, Larsson O, Axelson M, Lennartsson J, Hellman U, Carlson K, Ãsterborg A, Vanderkerken K, Nilsson K, Jernberg-Wiklund H,. 2006. IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells. Blood 107: 669-678.
31. Sui H, Wang Y, Liu X, Zhou L, Yin P, Zhou S-F, Fan Z, Li Q,. 2011. COX-2 contributes to P-glycoprotein-mediated multidrug resistance via phosphorylation of c-Jun at Ser63/73 in colorectal cancer. Carcinogenesis 32: 667-675.
32. Tanno S, Tanno S, Mitsuuchi Y, Altomare DA, Xiao G-H, Testa JR,. 2001. AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells. Cancer Res 61: 589-593.
33. Tarn C, Rink L, Merkel E, Flieder D, Pathak H, Koumbi D, Testa JR, Eisenberg B, von Mehren M, Godwin AK,. 2008. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci USA 105: 8387-8392.
34. Thompson AD, Kakar SS,. 2005. Insulin and IGF-1 regulate the expression of the pituitary tumor transforming gene (PTTG) in breast tumor cells. Febs Lett 579: 3195-3200.
35. Whittaker S, Marais R, Zhu AX,. 2010. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 29: 4989-5005.
36. Xu W, Liu JW, Li CL, Wu HZ, Liu YW,. 2008. Kaempferol-7-O-beta- D -glucoside (KG) isolated from Smilax china L. rhizome induces G(2)/M phase arrest and apoptosis on HeLa cells in a p53-independent manner. Cancer Lett 264: 229-240.
37. Young LC, Campling BG, Cole SPC, Deeley RG, Gerlach JH,. 2001. Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer. Clin Cancer Res 7: 1798-1804.